Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) fell 0.8% during trading on Friday . The stock traded as low as $17.16 and last traded at $17.33, with a volume of 66,440 shares trading hands. The stock had previously closed at $17.47.

Several brokerages have commented on BLCM. Zacks Investment Research upgraded Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research note on Monday. Jefferies Group restated a “buy” rating on shares of Bellicum Pharmacueticals in a research note on Tuesday, August 23rd. Piper Jaffray Cos. restated an “overweight” rating and issued a $31.00 price target (up from $25.00) on shares of Bellicum Pharmacueticals in a research note on Tuesday, August 9th. Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Tuesday, August 9th. Finally, SunTrust Banks Inc. initiated coverage on Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They issued a “buy” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $27.00.

The firm’s 50-day moving average is $16.76 and its 200-day moving average is $12.34. The company’s market cap is $466.31 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.04. During the same period in the prior year, the company earned ($0.40) EPS. Analysts anticipate that Bellicum Pharmacueticals Inc. will post ($2.34) EPS for the current fiscal year.

In related news, insider Kevin M. Slawin sold 67,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.31, for a total value of $1,293,770.00. Following the completion of the transaction, the insider now owns 100,079 shares of the company’s stock, valued at $1,932,525.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Kevin M. Slawin sold 2,719 shares of the business’s stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $13.99, for a total transaction of $38,038.81. Following the completion of the transaction, the chief technology officer now directly owns 134,206 shares of the company’s stock, valued at approximately $1,877,541.94. The disclosure for this sale can be found here.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.